The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Molecular pathogenesis and mechanisms of thyroid cancer
Open accessAbstract
Thyroid cancer is a common endocrine malignancy. There has been exciting progress in understanding its molecular pathogenesis in recent years, as best exemplified by the elucidation of the fundamental role of several major signalling pathways and related molecular derangements. Central to these mechanisms are the genetic and epigenetic alterations in these pathways, such as mutation, gene copy-number gain and aberrant gene methylation. Many of these molecular alterations represent novel diagnostic and prognostic molecular markers and therapeutic targets for thyroid cancer, which provide unprecedented opportunities for further research and clinical development of novel treatment strategies for this cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Self-citationBrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology
Alexander, E. K., Kennedy, G. C., Baloch, Z. W., Cibas, E. S., Chudova, D., Diggans, J., Friedman, L., Kloos, R. T., LiVolsi, V. A., Mandel, S. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203208 · Cited by 1,163
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Two G Protein Oncogenes in Human Endocrine Tumors
Lyons, J., Landis, C. A., Harsh, G., Vallar, L., Grünewald, K., Feichtinger, H., Duh, Q.-Y., Clark, O. H., Kawasaki, E., Bourne, H. R., et al. (1990) · Science · doi:10.1126/science.2116665 · Cited by 1,037
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Self-citationXing, M. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0007 · Cited by 983
Self-citationBRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
Self-citationSomatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas
Parma, J., Duprez, L., Sande, J. V., Cochaux, P., Gervy, C., Mockel, J., Dumont, J., & Vassart, G. (1993) · Nature · doi:10.1038/365649a0 · Cited by 918
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
A Conserved MST-FOXO Signaling Pathway Mediates Oxidative-Stress Responses and Extends Life Span
Lehtinen, M. K., Yuan, Z., Boag, P. R., Yang, Y., Villén, J., Becker, E. B. E., DiBacco, S., de la Iglesia, N., Gygi, S., Blackwell, T. K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.046 · Cited by 839
NF- B as a Critical Link Between Inflammation and Cancer
Karin, M. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000141 · Cited by 816
Nikiforov, Y. E., Ohori, N. P., Hodak, S. P., Carty, S. E., LeBeau, S. O., Ferris, R. L., Yip, L., Seethala, R. R., Tublin, M. E., Stang, M. T., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1469 · Cited by 790
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 713
The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation
van der HEIDE, L. P., HOEKMAN, M. F. M., & SMIDT, M. P. (2004) · Biochemical Journal · doi:10.1042/bj20040167 · Cited by 691
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., & Koeffler, H. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116168 · Cited by 649
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 541
Boelaert, K., Horacek, J., Holder, R. L., Watkinson, J. C., Sheppard, M. C., & Franklyn, J. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0527 · Cited by 534
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030305 · Cited by 533
Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
Haymart, M. R., Repplinger, D. J., Leverson, G. E., Elson, D. F., Sippel, R. S., Jaume, J. C., & Chen, H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2215 · Cited by 499
The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer
Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O. H., Duh, Q.-Y., Shibru, D., Bastian, B., & Griffin, A. (2007) · Annals of Surgery · doi:10.1097/sla.0b013e318148563d · Cited by 480
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470
Proximity of Chromosomal Loci That Participate in Radiation-Induced Rearrangements in Human Cells
Nikiforova, M. N., Stringer, J. R., Blough, R., Medvedovic, M., Fagin, J. A., & Nikiforov, Y. E. (2000) · Science · doi:10.1126/science.290.5489.138 · Cited by 468
Kimura, T., Van Keymeulen, A., Golstein, J., Fusco, A., Dumont, J. E., & Roger, P. P. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.5.0444 · Cited by 464
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
Ciampi, R., Knauf, J. A., Kerler, R., Gandhi, M., Zhu, Z., Nikiforova, M. N., Rabes, H. M., Fagin, J. A., & Nikiforov, Y. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523237 · Cited by 461
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
Rabes, H. M., Demidchik, E. P., Sidorow, J. D., Lengfelder, E., Beimfohr, C., Hoelzel, D., & Klugbauer, S. (2000) · PubMed · Cited by 428
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 421
Hou, P., Liu, D., Shan, Y., Hu, S., Studeman, K., Condouris, S., Wang, Y., Trink, A., El-Naggar, A. K., Tallini, G., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1125 · Cited by 418
Self-citationHigh prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu, X., Quiros, R. M., Gattuso, P., Ain, K. B., & Prinz, R. A. (2003) · PubMed · Cited by 415
Knauf, J. A., Ma, X., Smith, E. P., Zhang, L., Mitsutake, N., Liao, X.-H., Refetoff, S., Nikiforov, Y. E., & Fagin, J. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0047 · Cited by 414
Kim, T. H., Park, Y. J., Lim, J. A., Ahn, H. Y., Lee, E. K., Lee, Y. J., Kim, K. W., Hahn, S. K., Youn, Y. K., Kim, K. H., et al. (2012) · Cancer · doi:10.1002/cncr.26500 · Cited by 400
BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism
Durante, C., Puxeddu, E., Ferretti, E., Morisi, R., Moretti, S., Bruno, R., Barbi, F., Avenia, N., Scipioni, A., Verrienti, A., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2707 · Cited by 397
Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations
Gudmundsson, J., Sulem, P., Gudbjartsson, D. F., Jonasson, J. G., Sigurdsson, A., Bergthorsson, J. T., He, H., Blondal, T., Geller, F., Jakobsdottir, M., et al. (2009) · Nature Genetics · doi:10.1038/ng.339 · Cited by 392
Chakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Liu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Self-citationRivera, M., Ricarte-Filho, J., Knauf, J., Shaha, A., Tuttle, M., Fagin, J. A., & Ghossein, R. A. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.112 · Cited by 386
Giordano, T. J., Kuick, R., Thomas, D. G., Misek, D. E., Vinco, M., Sanders, D., Zhu, Z., Ciampi, R., Roh, M., Shedden, K., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208822 · Cited by 383
Riesco-Eizaguirre, G., Gutiérrez-Martínez, P., García-Cabezas, M. A., Nistal, M., & Santisteban, P. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01119 · Cited by 376
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d-9laj-trct-g6qd · Cited by 371
Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., & Pierotti, M. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116385 · Cited by 370
ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer
Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., & Tallini, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.130 · Cited by 368
Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d9lajtrctg6qd · Cited by 355
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors
Vasko, V., Ferrand, M., Di Cristofaro, J., Carayon, P., Henry, J. F., & de Micco, C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021186 · Cited by 310
Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.
Garcia-Rostan, G., Tallini, G., Herrero, A., D'Aquila, T. G., Carcangiu, M. L., & Rimm, D. L. (1999) · PubMed · Cited by 308
Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Dahia, P. L. M., Marsh, D. J., Zheng, Z., Zedenius, J., Komminoth, P., Frisk, T., Wallin, G., Parsons, R. E., Longy, M., Larsson, C., et al. (1997) · PubMed · Cited by 306
IQGAPs in cancer: A family of scaffold proteins underlying tumorigenesis
White, C. D., Brown, M. D., & Sacks, D. B. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.05.007 · Cited by 306
Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
Xing, M. (2010) · Thyroid · doi:10.1089/thy.2010.1646 · Cited by 305
Self-citationFrequent mutation and nuclear localization of betacatenin in anaplastic thyroid carcinoma
Gineza, G. (1999) · Cancer Research · Cited by 303
Overexpression and overactivation of Akt in thyroid carcinoma.
Ringel, M. D., Hayre, N., Saito, J., Saunier, B., Schuppert, F., Burch, H., Bernet, V., Burman, K. D., Kohn, L. D., & Saji, M. (2001) · PubMed · Cited by 297
BRAF mutations in papillary carcinomas of the thyroid
Fukushima, T., Suzuki, S., Mashiko, M., Ohtake, T., Endo, Y., Takebayashi, Y., Sekikawa, K., Hagiwara, K., & Takenoshita, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206739 · Cited by 297
β-Catenin Dysregulation in Thyroid Neoplasms
Garcia-Rostan, G., Camp, R. L., Herrero, A., Carcangiu, M. L., Rimm, D. L., & Tallini, G. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64045-x · Cited by 277
Riesco-Eizaguirre, G., Rodríguez, I., De la Vieja, A., Costamagna, E., Carrasco, N., Nistal, M., & Santisteban, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1248 · Cited by 265
Fiore, E., Rago, T., Provenzale, M. A., Scutari, M., Ugolini, C., Basolo, F., Di Coscio, G., Berti, P., Grasso, L., Elisei, R., et al. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0036 · Cited by 254
Trovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
Xing, M., Tufano, R. P., Tufaro, A. P., Basaria, S., Ewertz, M., Rosenbaum, E., Byrne, P. J., Wang, J., Sidransky, D., & Ladenson, P. W. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032050 · Cited by 251
Self-citationDiscovery of common variants associated with low TSH levels and thyroid cancer risk
Gudmundsson, J., Sulem, P., Gudbjartsson, D. F., Jonasson, J. G., Masson, G., He, H., Jonasdottir, A., Sigurdsson, A., Stacey, S. N., Johannsdottir, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.1046 · Cited by 244
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522758 · Cited by 242
RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis
Ciampi, R., & Nikiforov, Y. E. (2007) · Endocrinology · doi:10.1210/en.2006-0921 · Cited by 241
Elisei, R., Viola, D., Torregrossa, L., Giannini, R., Romei, C., Ugolini, C., Molinaro, E., Agate, L., Biagini, A., Lupi, C., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1775 · Cited by 237
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice
Franco, A. T., Malaguarnera, R., Refetoff, S., Liao, X.-H., Lundsmith, E., Kimura, S., Pritchard, C., Marais, R., Davies, T. F., Weinstein, L. S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015557108 · Cited by 223
Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kurokawa, K., Murakumo, Y., Imai, T., Funahashi, H., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203799 · Cited by 223
Fahey, T. J. (2006) · Yearbook of Surgery · doi:10.1016/s0090-3671(08)70420-8 · Cited by 218
Máximo, V, Botelho, T., Capela, J., Soares, P., Lima, J., Taveira, A., Amaro, T., Barbosa, A. P., Preto, A., Harach, H. R., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602547 · Cited by 214
Vasko, V, Saji, M., Hardy, E., Kruhlak, M., Larin, A., Savchenko, V, Miyakawa, M., Isozaki, O., Murakami, H., Tsushima, T., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.015339 · Cited by 211
Prognostic utility of BRAF mutation in papillary thyroid cancer
Xing, M. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.012 · Cited by 210
Self-citationSantarpia, L., El-Naggar, A. K., Cote, G. J., Myers, J. N., & Sherman, S. I. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1076 · Cited by 208
Dwight, T., Thoppe, S. R., Foukakis, T., Lui, W. O., Wallin, G., Höög, A., Frisk, T., Larsson, C., & Zedenius, J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021690 · Cited by 208
Cohen, Y., Rosenbaum, E., Clark, D. P., Zeiger, M. A., Umbricht, C. B., Tufano, R. P., Sidransky, D., & Westra, W. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0273 · Cited by 207
Tuttle, R. M., Ball, D. W., Byrd, D., Dilawari, R. A., Doherty, G. M., Duh, Q.-Y., Ehya, H., Farrar, W. B., Haddad, R. I., Kandeel, F., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0093 · Cited by 206
Liu, D., Hu, S., Hou, P., Jiang, D., Condouris, S., & Xing, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1753 · Cited by 202
Self-citationAhmed, M., Barbachano, Y., Riddell, A., Hickey, J., Newbold, K. L., Viros, A., Harrington, K. J., Marais, R., & Nutting, C. M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0129 · Cited by 201
Hu, S., Liu, D., Tufano, R. P., Carson, K. A., Rosenbaum, E., Cohen, Y., Holt, E. H., Kiseljak‐Vassiliades, K., Rhoden, K. J., Tolaney, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22110 · Cited by 197
Self-citationRole of the Tumor Suppressor RASSF1A in Mst1-Mediated Apoptosis
Oh, H. J., Lee, K.-K., Song, S. J., Jin, M. S., Song, M. S., Lee, J. H., Im, C. R., Lee, J.-O., Yonehara, S., & Lim, D.-S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2951 · Cited by 196
Volante, M., Rapa, I., Gandhi, M., Bussolati, G., Giachino, D., Papotti, M., & Nikiforov, Y. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1233 · Cited by 193
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Murugan, A. K., & Xing, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4041 · Cited by 193
Self-citationUncommon Mutation, but Common Amplifications, of the PIK3CA Gene in Thyroid Tumors
Wu, G., Mambo, E., Guo, Z., Hu, S., Huang, X., Gollin, S. M., Trink, B., Ladenson, P. W., Sidransky, D., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2281 · Cited by 191
Self-citationThe PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors
Saji, M., & Ringel, M. D. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.016 · Cited by 190
Suzuki, H., Willingham, M. C., & Cheng, S.-Y. (2002) · Thyroid · doi:10.1089/105072502320908295 · Cited by 190
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture
Santoro, M., Melillo, R. M., & Fusco, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02289 · Cited by 190
Basolo, F., Torregrossa, L., Giannini, R., Miccoli, M., Lupi, C., Sensi, E., Berti, P., Elisei, R., Vitti, P., Baggiani, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0337 · Cited by 182
Lin, K.-L., Wang, O.-C., Zhang, X.-H., Dai, X.-X., Hu, X.-Q., & Qu, J.-M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1129-6 · Cited by 175
Gene Methylation in Thyroid Tumorigenesis
Xing, M. (2007) · Endocrinology · doi:10.1210/en.2006-0927 · Cited by 174
Self-citationWang, Y., Hou, P., Yu, H., Wang, W., Ji, M., Zhao, S., Yan, S., Sun, X., Liu, D., Shi, B., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2019 · Cited by 172
Self-citationKnauf, J. A., Sartor, M. A., Medvedovic, M., Lundsmith, E., Ryder, M., Salzano, M., Nikiforov, Y. E., Giordano, T. J., Ghossein, R. A., & Fagin, J. A. (2011) · Oncogene · doi:10.1038/onc.2011.44 · Cited by 170
Abubaker, J., Jehan, Z., Bavi, P., Sultana, M., Al-Harbi, S., Ibrahim, M., Al-Nuaim, A., Ahmed, M., Amin, T., Al-Fehaily, M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1717 · Cited by 169
B-Raf V600E and thrombospondin-1 promote thyroid cancer progression
Nucera, C., Porrello, A., Antonello, Z. A., Mekel, M., Nehs, M. A., Giordano, T. J., Gerald, D., Benjamin, L. E., Priolo, C., Puxeddu, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004934107 · Cited by 168
Visconti, R., Cerutti, J., Battista, S., Fedele, M., Trapasso, F., Zeki, K., Miano, M. P., de Nigris, F., Casalino, L., Curcio, F., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201373 · Cited by 168
Hypoxia-induced Angiogenesis during Carcinogenesis
Choe, G.-S., Bae, M.-G., Jeong, J.-W., Mun, H.-E., & Kim, G.-W. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.120 · Cited by 165
Ikenoue, T., Hikiba, Y., Kanai, F., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., Kawakami, T., et al. (2003) · PubMed · Cited by 164
PTEN Promoter Methylation in Sporadic Thyroid Carcinomas
Álvarez-Núñez, F., Bussaglia, E., Mauricio, D., Ybarra, J., Vilar, M., Lerma, E., de Leiva, A., & Matías‐Guiu, X. (2006) · Thyroid · doi:10.1089/thy.2006.16.17 · Cited by 164
Jo, Y. S., Li, S., Song, J. H., Kwon, K. H., Lee, J. C., Rha, S. Y., Lee, H. J., Sul, J. Y., Kweon, G. R., Ro, H.-K., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2836 · Cited by 160
Romei, C., Ciampi, R., Faviana, P., Agate, L., Molinaro, E., Bottici, V., Basolo, F., Miccoli, P., Pacini, F., Pinchera, A., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0130 · Cited by 160
Basolo, F., Pisaturo, F., Pollina, L. E., Fontanini, G., Elisei, R., Molinaro, E., Iacconi, P., Miccoli, P., & Pacini, F. (2000) · Thyroid · doi:10.1089/thy.2000.10.19 · Cited by 155
Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin, U., Gimm, O., Hoang‐Vu, C., Dralle, H., Pfeifer, G. P., & Dammann, R. (2002) · PubMed · Cited by 149
Gustafson, S. L., Zbuk, K. M., Scacheri, C., & Eng, C. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.07.009 · Cited by 148
Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor
Furuya, F., Hanover, J. A., & Cheng, S.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510849103 · Cited by 147
Bruni, P., Boccia, A. S., Baldassarre, G., Trapasso, F., Santoro, M., Chiappetta, G., Fusco, A., & Viglietto, G. (2000) · Oncogene · doi:10.1038/sj.onc.1203633 · Cited by 145
Xing, M., Cohen, Y., Mambo, E., Tallini, G., Udelsman, R., Ladenson, P. W., & Sidransky, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3242 · Cited by 143
Self-citationThe Primary Occurrence ofBRAFV600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma
Guerra, A., Sapio, M. R., Marotta, V., Campanile, E., Rossi, S., Forno, I., Fugazzola, L., Budillon, A., Moccia, T., Fenzi, G., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0618 · Cited by 140
Hou, P., Bojdani, E., & Xing, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1888 · Cited by 138
Self-citationFukahori, M., Yoshida, A., Hayashi, H., Yoshihara, M., Matsukuma, S., Sakuma, Y., Koizume, S., Okamoto, N., Kondo, T., Masuda, M., et al. (2012) · Thyroid · doi:10.1089/thy.2011.0261 · Cited by 137
Hou, P., Ji, M., & Xing, M. (2008) · Cancer · doi:10.1002/cncr.23869 · Cited by 136
Self-citationRole of NF-κB in thyroid cancer
Pacifico, F., & Leonardi, A. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.010 · Cited by 136
Mesa, C. O., Mirza, M., Mitsutake, N., Sartor, M. A., Medvedovic, M., Tomlinson, C. R., Knauf, J. A., Weber, G. F., & Fagin, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0739 · Cited by 136
Murugan, A. K., Bojdani, E., & Xing, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.095 · Cited by 135
Self-citationHigh Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma
Henderson, Y. C., Shellenberger, T. D., Williams, M. D., El‐Naggar, A. K., Fredrick, M. J., Cieply, K. M., & Clayman, G. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0933 · Cited by 132
Gene rearrangement and Chernobyl related thyroid cancers
Santoro, M. M., Thomas, G. A. O., Vecchio, G., Williams, G. H., Fusco, A., Chiappetta, G., Pozcharskaya, V., Ti, B., Demidchik, E. P., Cherstvoy, E. D., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0921 · Cited by 130
Costa, Â. M., Herrero, A., Fresno, M., Heymann, J. J., Alvarez, J. A., Cameselle‐Teijeiro, J., & García‐Rostán, G. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03077.x · Cited by 129
Miller, K. A., Yeager, N., Baker, K., Liao, X.-H., Refetoff, S., & Cristofano, A. D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0024 · Cited by 129
Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake
Mian, C., Barollo, S., Pennelli, G., Pavan, N., Rugge, M., Pelizzo, M. R., Mazzarotto, R., Casara, D., Nacamulli, D., Mantero, F., et al. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03008.x · Cited by 129
Mitsiades, C. S., McMillin, D. W., Kotoula, V., Poulaki, V., McMullan, C. J., Negri, J. M., Fanourakis, G., Tseleni‐Balafouta, S., Ain, K. B., & Mitsiades, N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2472 · Cited by 128
Role of the Wnt Pathway in Thyroid Cancer
Sastre-Perona, A., & Santisteban, P. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00031 · Cited by 127
Leboeuf, R., Baumgartner, J. E., Benezra, M., Malaguarnera, R., Solit, D. B., Pratilas, C. A., Rosen, N. X., Knauf, J. A., & Fagin, J. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2825 · Cited by 127
Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas
Manenti, G., Pilotti, S., Re, F. C., Porta, G., & Pierotti, M. A. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90130-9 · Cited by 126
Liu, D., Liu, Z., Condouris, S., & Xing, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1613 · Cited by 126
Self-citationOler, G., & Cerutti, J. M. (2009) · Cancer · doi:10.1002/cncr.24118 · Cited by 123
Vasko, V. V., Hu, S., Wu, G., Xing, J. C., Ларін, О. С., Savchenko, V., Trink, B., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2353 · Cited by 121
Self-citationCostamagna, E., García, B., & Santisteban, P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307138200 · Cited by 120
Oxidative stress: a new risk factor for thyroid cancer
Xing, M. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0360 · Cited by 120
Self-citationBRAFV600EPromotes Invasiveness of Thyroid Cancer Cells through Nuclear Factor κB Activation
Palona, I., Namba, H., Mitsutake, N., Starenki, D., Podtcheko, A., Sedliarou, I., Ohtsuru, A., Saenko, V., Nagayama, Y., Umezawa, K., et al. (2006) · Endocrinology · doi:10.1210/en.2006-0400 · Cited by 112
Kogai, T., Sajid-Crockett, S., Newmarch, L. S., Liu, Y., & Brent, G. A. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0333 · Cited by 111
Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse
Charles, R., Iezza, G., Amendola, E., Dankort, D. L., & McMahon, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4463 · Cited by 110
Ball, D. W., Jin, N. Y., Rosen, D. M., Dackiw, A. P. B., Sidransky, D., Xing, M., & Nelkin, B. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1184 · Cited by 109
Self-citationAKT Activation Promotes Metastasis in a Mouse Model of Follicular Thyroid Carcinoma
Kim, C. S., Vasko, V. V., Kato, Y., Kruhlak, M. J., Saji, M., Cheng, S.-Y., & Ringel, M. D. (2005) · Endocrinology · doi:10.1210/en.2005-0172 · Cited by 108
Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer
Frisk, T., Foukakis, T., Dwight, T., Lundberg, J., Höög, A., Wallin, G., Eng, C., Zedenius, J., & Larsson, C. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10098 · Cited by 107
Liu, R., Liu, D., Trink, E., Bojdani, E., Ning, G., & Xing, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2644 · Cited by 107
Self-citationExpression of hypoxia-inducible factor 1α in thyroid carcinomas
Burrows, N., Resch, J., Cowen, R. L., von Wasielewski, R., Hoang‐Vu, C., West, C., Williams, K. J., & Brabant, G. E. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0251 · Cited by 107
Oncogenic and Anti-apoptotic Activity of NF-κB in Human Thyroid Carcinomas
Pacifico, F., Mauro, C., Barone, C., Crescenzi, E., Mellone, S., Monaco, M., Chiappetta, G., Terrazzano, G., Liguoro, D., Vito, P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403492200 · Cited by 103
Oler, G., Camacho, C. P., Hojaij, F. C., Michaluart, P., Riggins, G. J., & Cerutti, J. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4372 · Cited by 102
Schagdarsurengin, U., Gimm, O., Dralle, H., Hoang‐Vu, C., & Dammann, R. (2006) · Thyroid · doi:10.1089/thy.2006.16.633 · Cited by 101
BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression
Nucera, C., Lawler, J., & Parangi, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3844 · Cited by 101
RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint
Marotta, V., Guerra, A., Sapio, M. R., & Vitale, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0499 · Cited by 101
The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer
Eberhardt, N. L., Grebe, S. K. G., McIver, B., et al. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.013 · Cited by 100
Salerno, P., Falco, V. D., Tamburrino, A., Nappi, T. C., Vecchio, G., Schweppe, R. E., Bollag, G. E., Santoro, M. M., & Salvatore, G. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0373 · Cited by 98
MTOR downregulates iodide uptake in thyrocytes
de Souza, E. C. L., de Figueiredo, Á. S. P., Braga, W. M. O., de Andrade, B. M., Vaisman, M., Nasciutti, L. E., Ferreira, A. C. F., & de Carvalho, D. P. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0436 · Cited by 96
PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer
Guigon, C. J., Zhao, L., Willingham, M. C., & Cheng, S.-Y. (2008) · Oncogene · doi:10.1038/onc.2008.407 · Cited by 94
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Jin, N. Y., Jiang, T., Rosen, D. M., Nelkin, B. D., & Ball, D. W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0933 · Cited by 90
PI3K Is Involved in the IGF-I Inhibition of TSH-Induced Sodium/Iodide Symporter Gene Expression
García, B., & Santisteban, P. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.2.0774 · Cited by 89
Liu, D., Hou, P., Liu, Z., Wu, G., & Xing, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1077 · Cited by 88
Self-citationCastellone, M. D., Falco, V. D., Rao, D. M., Bellelli, R., Muthu, M., Basolo, F., Fusco, A., Gutkind, J. S., & Santoro, M. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1982 · Cited by 88
Hou, P., Liu, D., & Xing, M. (2007) · Cell Cycle · doi:10.4161/cc.6.3.3818 · Cited by 87
Self-citationJoo, J.-Y., Park, J., Yoon, Y., Choi, B., Kim, J., Jo, Y. S., Shong, M., & Koo, B. S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2444 · Cited by 86
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas
Hemerly, J. P., Bastos, A. U., & Cerutti, J. M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0473 · Cited by 84
Hou, P., Liu, D., & Xing, M. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0212 · Cited by 84
Self-citationScarpino, S., d’Alena, F. C., Napoli, A. D., Pasquini, A., Marzullo, A., & Ruco, L. (2004) · The Journal of Pathology · doi:10.1002/path.1522 · Cited by 79
Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications
Xing, M. (2008) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2008.07.001 · Cited by 77
Self-citationIkenoue, T., Hikiba, Y., Kanai, F., Aragaki, J., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3591 · Cited by 77
Ying, H., Suzuki, H., Zhao, L., Willingham, M. C., Meltzer, P. S., & Cheng, S.-Y. (2003) · PubMed · Cited by 76
Liu, D., & Xing, M. (2008) · Thyroid · doi:10.1089/thy.2007.0357 · Cited by 71
Self-citationThe Nuclear Factor Kappa-B Signaling Pathway as a Therapeutic Target Against Thyroid Cancers
Li, X., Abdel‐Mageed, A. B., Mondal, D., & Kandil, E. H. (2012) · Thyroid · doi:10.1089/thy.2012.0237 · Cited by 69
High Growth Rate of Benign Thyroid Nodules Bearing RET/PTC Rearrangements
Sapio, M. R., Guerra, A., Marotta, V., Campanile, E., Formisano, R., Deandrea, M., Motta, M., Limone, P. P., Fenzi, G., Rossi, G., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1599 · Cited by 68
Liu, D., Liu, Z., JIANG, D., Dackiw, A. P. B., & Xing, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0097 · Cited by 67
Self-citationIQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer
Liu, Z., Liu, D., Bojdani, E., El‐Naggar, A. K., Vasko, V. V., & Xing, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1627 · Cited by 64
Self-citationNowicki, T. S., Zhao, H. L., Darżynkiewicz, Z., Moscatello, A. L., Shin, E. D., Schantz, S., Tiwari, R. K., & Geliebter, J. (2011) · Cell Cycle · doi:10.4161/cc.10.1.14362 · Cited by 63
Burrows, N., Babur, M., Resch, J., Ridsdale, S., Mejin, M., Rowling, E. J., Brabant, G. E., & Williams, K. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1426 · Cited by 62
Liu, D., Xing, J., Trink, B., & Xing, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25304 · Cited by 61
Self-citationBarollo, S., Pennelli, G., Vianello, F., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0290 · Cited by 61
In vitro reconstruction of tumour initiation in a human epithelium.
Bond, J. A., Wyllie, F. S., Rowson, J., Radulescu, A., & Wynford‐Thomas, D. (1994) · PubMed · Cited by 61
BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas
Lee, J. H., Lee, E. S., Kim, Y., Won, N. H., & Chae, Y. (2006) · Pathology · doi:10.1080/00313020600696264 · Cited by 60
The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer
Placzkowski, K. A., Reddi, H. V., Grebe, S. K. G., Eberhardt, N. L., & McIver, B. (2008) · PPAR Research · doi:10.1155/2008/672829 · Cited by 60
Xing, J., Liu, R., Xing, M., & Trink, B. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.088 · Cited by 58
Self-citationLiu, R., Liu, D., & Xing, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1054 · Cited by 58
Self-citationMultiple Signaling Pathways Converge on β-Catenin in Thyroid Cancer
Abbosh, P. H., & Nephew, K. P. (2005) · Thyroid · doi:10.1089/thy.2005.15.551 · Cited by 56
BRAF mutation influences hypoxia-inducible factor-1α expression levels in papillary thyroid cancer
Zerilli, M., Zito, G., Martorana, A., Pitrone, M., Cabibi, D., Cappello, F., Giordano, C. S. D. S., & Rodolico, V. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.86 · Cited by 52
Miyagi, E., Braga‐Basaria, M., Hardy, E., Vasko, V. V., Burman, K. D., Jhiang, S. M., Saji, M., & Ringel, M. D. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20042 · Cited by 50
Gire, V., & Wynford‐Thomas, D. (2000) · Oncogene · doi:10.1038/sj.onc.1203399 · Cited by 49
Lee, S. J., Lee, M. H., Kim, D. W., Lee, S., Huang, S., Ryu, M. J., Kim, Y. K., Kim, S. J., Kim, S. J., Hwang, J. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016180 · Cited by 46
Pasquali, D., Santoro, A., Bufo, P., Conzo, G., Deery, W. J., Renzullo, A., Accardo, G., Sacco, V., Bellastella, A., & Pannone, G. (2011) · Thyroid · doi:10.1089/thy.2010.0168 · Cited by 40
Use of sodium iodide symporter expression in differentiated thyroid carcinomas
Morari, E. C., Marcello, M. A., Guilhen, A. C. T., Cunha, L. L., Latuff, P., Soares, F. A., Vassallo, J., & Ward, L. S. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04032.x · Cited by 39
Lai, M. B., Bhardwaj, V., Lai, J. C. K., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4403 · Cited by 38
The effect Akt2 deletion on tumor development in Pten+/− mice
Xu, P.-Z., Chen, M.-L., Jeon, S.-M., Peng, X.-D., & Hay, N. (2011) · Oncogene · doi:10.1038/onc.2011.243 · Cited by 34
MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner
Vadysirisack, D. D., Venkateswaran, A., Zhang, Z., & Jhiang, S. M. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01263 · Cited by 34
FGFR2 Isoforms Support Epithelial–Stromal Interactions in Thyroid Cancer Progression
Guo, M., Liu, W., Serra, S., Asa, S. L., & Ezzat, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3985 · Cited by 32
Raf-induced transformation requires an interleukin 1 autocrine loop.
Vale, T., Ngo, T.-T. B., White, M. A., & Lipsky, P. E. (2001) · PubMed · Cited by 31
Schweppe, R. E., Kerege, A. A., Sharma, V., Poczobutt, J. M., Gutierrez‐Hartmann, A., Grzywa, R. L., & Haugen, B. R. (2009) · Thyroid · doi:10.1089/thy.2008.0362 · Cited by 28
Possible Involvement of BRAFV600E in Altered Gene Expression in Papillary Thyroid Cancer
Watanabe, R., Hayashi, Y., Sassa, M., Kikumori, T., Imai, T., Kiuchi, T., & Murata, Y. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-329 · Cited by 27
BRAF V600E Mutation and Papillary Thyroid Cancer: Chicken or Egg?
Xing, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2201 · Cited by 27
Self-citationInhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells
Nowicki, T. S., Kummer, N. T., Iacob, C. E., Suslina, N., Schaefer, S. D., Schantz, S., Shin, E. D., Moscatello, A. L., Tiwari, R. K., & Geliebter, J. (2010) · The Laryngoscope · doi:10.1002/lary.20915 · Cited by 25
Genetic-Targeted Therapy of Thyroid Cancer: A Real Promise
Xing, M. (2009) · Thyroid · doi:10.1089/thy.2009.1583 · Cited by 10
Self-citation
Cited by
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Nikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., et al. (2013) · JAMA · doi:10.1001/jama.2013.3190 · Cited by 940
Self-citationXing, M., Liu, R., Liu, X., Murugan, A. K., Zhu, G., Zeiger, M. A., Pai, S., & Bishop, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5094 · Cited by 725
Self-citation
Metadata
- Authors
- Xing, M.
- Venue
- Nature Reviews Cancer
- Published
- 2013-02-22
- Volume
- 13
- Issue
- 3
- Pages
- 184-199
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2069792474
- Cited by
- 1,426
- References
- 195
- FWCI
- 17.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.